Discovery of 3 Key Pancreatic Cancer Oncogenes and Targeted Therapy Candidates via Multi-Cohort Transcriptome Network Analysis
Background
Pancreatic ductal adenocarcinoma (PDAC) is a representative intractable malignancy with a 5-year relative survival rate of around 10%. Most cases are detected at advanced stages where surgery is impossible, and they rapidly develop resistance to standard chemotherapies like gemcitabine or FOLFIRINOX. The dense fibrous connective tissue matrix tightly surrounding cancer cells impedes drug penetration, resulting in treatment response rates remaining at the lowest levels.
Despite large-scale cancer genome projects identifying major mutations like KRAS and TP53, the development of targeted therapies has faced a long period of stagnation. Experts point out that previous studies focused on single-mutation analysis struggled to capture the complex gene regulatory interaction networks within tumor cells. Furthermore, expression analyses based on small patient cohorts often failed during clinical validation due to high heterogeneity between cohorts. There was an urgent need for a multi-faceted computational biology framework to identify molecular targets and effective drugs that precisely target the core vulnerabilities of cancer cell survival networks.
Key Findings
The researchers developed a computational framework to construct large-scale co-expression networks by integrating transcriptomic big data from several independent PDAC clinical cohorts. After linking patient prognosis signature data, we precisely identified prognosis-associated functional modules through hypergeometric enrichment analysis. Subsequently, they applied multi-metric centrality analysis encompassing closeness centrality and betweenness centrality to identify the central regulatory factors within the network. Following strict filtering, 14 key genes that maintained high centrality across multiple cohorts were finalized.
In the functional validation stage, the researchers employed a method of comprehensively cross-referencing single-cell RNA sequencing (scRNA-seq) and genome-wide CRISPR dependency screening data. scRNA-seq analysis revealed that among the candidates, three types—Cytoskeleton-associated protein 2-like (CKAP2L), Kinesin family member 18A (KIF18A), and Minichromosome Maintenance Complex Component 10 (MCM10)—were specifically elevated in epithelial tumor cells rather than stromal cells. Clinical survival analysis of large patient cohorts clearly demonstrated that high expression of these three genes is directly linked to shortened patient survival. CRISPR loss-of-function screening data provided decisive evidence that these three genes are essential drivers sustaining the survival and division of PDAC cells.
To drive therapeutic translation, a compound perturbation profile matching strategy using the Library of Integrated Network-based Cellular Signatures (LINCS) was employed. This algorithm ranks small-molecule compounds that revert PDAC-specific transcriptomic expression patterns to normal levels using a cross-cohort consensus scoring system. As a result, Mitoxantrone and OTSSP167 were selected as CKAP2L inhibition candidates, PF-3758309 as a KIF18A inhibition candidate, and Borinostat as an MCM10 inhibition candidate. In laboratory validations, including quantitative reverse transcription PCR (qRT-PCR), Western blot, and CCK-8 cell viability assays, these candidate drugs inhibited the mRNA and protein expression of target genes in a concentration-dependent manner and strongly suppressed cancer cell proliferation.
Significance and Outlook
This achievement is evaluated as having seamlessly connected the previously fragmented processes of target discovery and drug screening within a computational network platform. By combining multi-cohort cross-validation with single-cell transcriptomics and functional genomics data, the reproducibility of the identified targets was significantly enhanced. In particular, it provided a clue to target difficult-to-access cell division and DNA replication regulatory factors using approved drugs or compounds with proven efficacy.
However, practical barriers to clinical implementation remain. Since validation has been primarily conducted using in vitro cell line models, it is pointed out that follow-up evaluations of drug penetration and in vivo pharmacokinetics are required in patient-derived organoids (PDO) and animal models that mimic the thick connective tissue characteristic of pancreatic cancer. Analysis suggests that optimizing dosage to minimize damage to normal pancreatic tissue and validating combination therapies with existing chemotherapies will be the keys to commercialization.
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited therapeutic options and an urgent need for novel treatment strategies. This study presented a network-based computational framework that integrates transcriptomic data from multiple independent PDAC cohorts to construct gene co-expression networks. Prognostic gene signatures were incorporated to identify feature modules via hypergeometric enrichment analysis. Key regulatory genes within these modules were prioritized using multi-metric centrality analysis. Functional relevance of candidate targets was assessed using single-cell ribonucleic acid (RNA) sequencing, genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) dependency datasets, and clinical survival analyses. To enable therapeutic translation, this study implemented a transcriptome-guided drug discovery strategy to systematically match pancreatic ductal adenocarcinoma (PDAC)-specific gene expression signatures with compound-induced transcriptional profiles from the Library of Integrated Network-based Cellular Signatures (LINCS) database. Candidate compounds were ranked using a cross-cohort consensus scoring approach and subsequently evaluated. RESULTS: Comprehensive analysis of multi-cohort PDAC transcriptomic data identified 14 key genes with high network centrality, including three potential oncogenic drivers: Cytoskeleton associated protein 2 like ( CONCLUSION: This study establishes a robust, network-based framework for therapeutic target discovery and transcriptome-driven drug prediction in PDAC. It identifies three novel, functionally essential oncogenic drivers and proposes clinically actionable compounds, offering a scalable approach for addressing undruggable targets in cancer therapy.
The established network-based discovery system can serve as a practical tool to significantly reduce the time and astronomical costs required for drug development. It provides direct guidance for drug repurposing strategies, such as the rapid repurposing of drugs with established safety profiles, like mitoxantrone or vorinostat, as treatments for refractory pancreatic cancer. In actual clinical practice, a companion diagnostic strategy could be established by testing the expression levels of CKAP2L, KIF18A, and MCM10 in patient tumor biopsies to select patient groups likely to respond to specific drugs. If a precision medicine scenario in which these inhibitors are selectively prescribed as combination therapies for refractory patients who do not respond to standard anticancer drugs becomes a reality, it is expected to mark a substantial turning point in improving patient survival rates.